Overview

Linagliptin Add-on to Insulin Background Therapy

Status:
Completed

Trial end date:
2019-01-18

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Eli Lilly and Company

Treatments:

Insulin
Linagliptin